Movatterモバイル変換


[0]ホーム

URL:


AU1992592A - Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors - Google Patents

Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors

Info

Publication number
AU1992592A
AU1992592AAU19925/92AAU1992592AAU1992592AAU 1992592 AAU1992592 AAU 1992592AAU 19925/92 AAU19925/92 AAU 19925/92AAU 1992592 AAU1992592 AAU 1992592AAU 1992592 AAU1992592 AAU 1992592A
Authority
AU
Australia
Prior art keywords
drug
treatment
type
monoamine oxidase
withdrawal symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19925/92A
Inventor
George W. Belenduik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Pharmavene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmavene IncfiledCriticalPharmavene Inc
Publication of AU1992592ApublicationCriticalpatent/AU1992592A/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

AU19925/92A1991-05-241992-05-04Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitorsAbandonedAU1992592A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US70508591A1991-05-241991-05-24
US7050851991-05-24

Publications (1)

Publication NumberPublication Date
AU1992592Atrue AU1992592A (en)1993-01-08

Family

ID=24831978

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU19925/92AAbandonedAU1992592A (en)1991-05-241992-05-04Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors

Country Status (2)

CountryLink
AU (1)AU1992592A (en)
WO (1)WO1992021333A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
FR2713087B1 (en)*1993-11-301996-02-23Saurat Jean Hilaire Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis.
US6319954B1 (en)*1995-01-132001-11-20Somerset Pharmaceuticals, Inc.S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en)1995-01-132001-10-09Somerset Pharmaceuticals, Inc.Methods and pharmaceutical compositions employing desmethylselegiline
CA2212412A1 (en)*1995-02-101996-08-15The University Of Toronto Innovations FoundationDeprenyl compounds for treatment of glaucoma
JPH11506744A (en)1995-06-071999-06-15ノウブン ファーマシューティカルズ インク. Transdermal compositions containing low molecular weight drugs that are liquid at room temperature
US6316022B1 (en)1995-06-072001-11-13Noven Pharmaceuticals, Inc.Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19746191C2 (en)*1997-10-182000-05-18Lohmann Therapie Syst Lts Method of using an active ingredient-containing patch to combat or alleviate addiction
US6210705B1 (en)*1997-12-152001-04-03Noven Pharmaceuticals, Nc.Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US7083808B2 (en)1998-12-172006-08-01Euro-Celtique S.A.Controlled/modified release oral methylphenidate formulations
US6419960B1 (en)1998-12-172002-07-16Euro-Celtique S.A.Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en)1998-12-172004-01-06Euro-Celtique, S.A.Controlled/modified release oral methylphenidate formulations
US6280763B1 (en)1999-05-102001-08-28Pierce Management, LlcApparatus and method for transdermal delivery of bupropion
WO2003039525A1 (en)2001-11-052003-05-15Krele Pharmaceuticals LlcCompositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
IL165249A0 (en)2002-07-182005-12-18Cytos Biotechnology AgHapten-carrier conjugates and uses thereof
US7732162B2 (en)2003-05-052010-06-08Probiodrug AgInhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP1686973A4 (en)2003-11-252009-03-25Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS AND DISEASES
US8263655B2 (en)2005-10-062012-09-11Technion Research And Development Foundation LtdMethods for treatment of renal failure
DE102006038719A1 (en)2006-08-182008-02-21Tesa Ag Pressure-sensitive adhesive strips for moisture-resistant, removable adhesive bonds
US8278345B2 (en)2006-11-092012-10-02Probiodrug AgInhibitors of glutaminyl cyclase
US9126987B2 (en)2006-11-302015-09-08Probiodrug AgInhibitors of glutaminyl cyclase
CN101668525A (en)2007-03-012010-03-10前体生物药物股份公司New use of glutaminyl cyclase inhibitors
EP2142514B1 (en)2007-04-182014-12-24Probiodrug AGThiourea derivatives as glutaminyl cyclase inhibitors
BR112012008346B1 (en)2009-09-112021-12-21Vivoryon Therapeutics N.V. HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION
US9943489B2 (en)2010-02-032018-04-17Pharmatwob Ltd.Extended release formulations of rasagiline and uses thereof
EP2542549B1 (en)2010-03-032016-05-11Probiodrug AGInhibitors of glutaminyl cyclase
KR101790806B1 (en)2010-03-102017-11-20프로비오드룩 아게Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en)2010-04-212016-01-06Probiodrug AGInhibitors of glutaminyl cyclase
JP6355921B2 (en)2010-09-012018-07-11トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. Treatment of addiction to cocaine
ES2570167T3 (en)2011-03-162016-05-17Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
US9937144B2 (en)2013-01-302018-04-10The Johns Hopkins UniversityTreatment of drug abuse by preventing GAPDH nitrosylation
CA3018328A1 (en)2014-10-312016-04-30Purdue PharmaMethods and compositions particularly for treatment of attention deficit disorder
EP3461819B1 (en)2017-09-292020-05-27Probiodrug AGInhibitors of glutaminyl cyclase
US10722473B2 (en)2018-11-192020-07-28Purdue Pharma L.P.Methods and compositions particularly for treatment of attention deficit disorder

Also Published As

Publication numberPublication date
WO1992021333A3 (en)1993-01-07
WO1992021333A2 (en)1992-12-10

Similar Documents

PublicationPublication DateTitle
AU1992592A (en)Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
AU3419593A (en)Medicine reminder and storage device
CA2128044A1 (en)Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
WO1994012165A3 (en)Enzyme inhibitors
AU698101B2 (en)Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
AU2804489A (en)New device and new method for drug administration
AU1061988A (en)Phosphinothricin-resistance gene active in plants, and its use
NZ335146A (en)N-(N'-substituted glycyl)-2-cyanopyrrolidine derivatives and medicaments
AU6042696A (en)Drug delivery catheters and methods of use
AU2005388A (en)Method and device for vapor sterilization of articles having lumens
AU4342689A (en)Cryoablation catheter and method of performing cryoablation
EP0725659A4 (en)Percutaneous port catheter and method of use
AU1007788A (en)Proximal manifold and adapter
EP0648492A3 (en)Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof.
EP0428585A4 (en)Novel method of administering aspirin and dosage forms containing same
AU4263789A (en)Antimalarial compositions and methods of treatment using quinidine, artemisinine and its derivatives
AU6867787A (en)Process and kit for drug detection
AU7065694A (en)Catheter and method of use thereof
AU1846488A (en)Analgesic and anti-inflammatory thiourea derivatives
AU1279788A (en)Compounds and treatment
EP0313654A4 (en)Drug for prophylaxis and treatment of hepatopathy.
AU1956092A (en)Pharmaceutical agent for treatment of withdrawal symptoms
AU3075692A (en)Method of producing and treatment with tablet composition
HUP9901990A2 (en)Furan- and thiophene derivatives having inhibitor effect on the replication of hiv-1 and hiv-1 mutants, and medicaments containing the same
AU623165B2 (en)Method of inhibiting the spread of disease and infection in structures

[8]ページ先頭

©2009-2025 Movatter.jp